(VIANEWS) – GRAM CAR CARRIERS (GCC.OL), NAVAMEDIC (NAVA.OL), SPBK 1 ØSTLANDET (SPOL.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. GRAM CAR CARRIERS (GCC.OL)
81% sales growth and 19.55% return on equity
Gram Car Carriers ASA, through its subsidiaries, operates as a tonnage supplier worldwide. The company invests in and operates assets in the pure car and truck carrier shipping segment. It provides a fleet of vessels for various aspects of the seaborne vehicle transportation trade. The company also offers commercial management services for the 18 owned vehicles and 4 managed vessels owned by third parties. Gram Car Carriers ASA was founded in 2006 and is based in Oslo, Norway.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Sales Growth
GRAM CAR CARRIERS’s sales growth is 79.2% for the current quarter and 81% for the next.
More news about GRAM CAR CARRIERS.
2. NAVAMEDIC (NAVA.OL)
72.2% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr-1.14.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.6%, now sitting on 382.14M for the twelve trailing months.
Volume
Today’s last reported volume for NAVAMEDIC is 9382 which is 61.23% below its average volume of 24204.
Moving Average
NAVAMEDIC’s value is way above its 50-day moving average of kr36.02 and way higher than its 200-day moving average of kr32.99.
More news about NAVAMEDIC.
3. SPBK 1 ØSTLANDET (SPOL.OL)
26.4% sales growth and 10.09% return on equity
SpareBank 1 Østlandet provides various financial products and services to individuals, businesses, the public sector, clubs, and societies. The company offers deposits, financing, savings, advisory, life and non-life insurance, and pension products and services. It also provides credit cards; and leasing, money-transfer, capital and investment management, debt recovery, real estate brokering and rental, factoring, trade and corporate finance, and accounting related services. It has 36 branches in Innlandet, Oslo, and Viken. The company was founded in 1845 and is headquartered in Hamar, Norway. SpareBank 1 Østlandet is a subsidiary of Sparebankstiftelsen Hedmark.
Earnings Per Share
As for profitability, SPBK 1 ØSTLANDET has a trailing twelve months EPS of kr10.57.
PE Ratio
SPBK 1 ØSTLANDET has a trailing twelve months price to earnings ratio of 10.85. Meaning, the purchaser of the share is investing kr10.85 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.09%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 22.2% and 99%, respectively.
Sales Growth
SPBK 1 ØSTLANDET’s sales growth is 6.8% for the current quarter and 26.4% for the next.
More news about SPBK 1 ØSTLANDET.
4. SKUE SPAREBANK (SKUE.OL)
17% sales growth and 9.06% return on equity
Skue Sparebank provides various banking products and services for individual and business in Norway. The company offers operating, tax deduction, capital, client, deposit, and group accounts; business, construction, personal, vehicle, and small loans, as well as mortgage, bank guarantee, overdraft, and leasing services; and home and leisure, car and other vehicles, pet, company and employees, agriculture insurance products. It also provides savings and pension products; and online and mobile banking, bank card, and payment services. The company was formerly known as Nes Prestegjelds Sparebank and changed its name to Skue Sparebank in October 2013. Skue Sparebank was founded in 1842 and is based in Geilo, Norway.
Earnings Per Share
As for profitability, SKUE SPAREBANK has a trailing twelve months EPS of kr14.43.
PE Ratio
SKUE SPAREBANK has a trailing twelve months price to earnings ratio of 15.66. Meaning, the purchaser of the share is investing kr15.66 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.06%.
More news about SKUE SPAREBANK.
5. EQUASENS (EQS.PA)
11.3% sales growth and 28.59% return on equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Moving Average
EQUASENS’s value is below its 50-day moving average of €77.40 and below its 200-day moving average of €76.13.
Volume
Today’s last reported volume for EQUASENS is 1256 which is 67.66% below its average volume of 3884.
More news about EQUASENS.
6. PERNOD RICARD (RI.PA)
7.9% sales growth and 14.84% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. The company was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €9.19.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 22.77. Meaning, the purchaser of the share is investing €22.77 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.84%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 25, 2022, the estimated forward annual dividend rate is 4.12 and the estimated forward annual dividend yield is 2%.
More news about PERNOD RICARD.
7. ORKLA (ORK.OL)
6.6% sales growth and 12.77% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr4.37.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 17. Meaning, the purchaser of the share is investing kr17 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.77%.
Yearly Top and Bottom Value
ORKLA’s stock is valued at kr74.26 at 02:20 EST, way below its 52-week high of kr85.20 and way higher than its 52-week low of kr67.06.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 14, 2023, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 4.08%.
More news about ORKLA.
8. DASSAULT SYSTEMES (DSY.PA)
6% sales growth and 13.74% return on equity
Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS design software for mechanical and electronic printed circuit board design solutions, product data management, simulation, manufacturing, and technical communication; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for intersection of natural resources, infrastructure and urban planning; and BIOVIA that develops chemicals, biologics, and materials experiences. The company provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, DASSAULT SYSTEMES has a trailing twelve months EPS of €2.09.
PE Ratio
DASSAULT SYSTEMES has a trailing twelve months price to earnings ratio of 18.01. Meaning, the purchaser of the share is investing €18.01 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.74%.
Yearly Top and Bottom Value
DASSAULT SYSTEMES’s stock is valued at €37.65 at 02:20 EST, way under its 52-week high of €46.55 and way higher than its 52-week low of €32.23.
More news about DASSAULT SYSTEMES.
